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GDF15	 (growth	differentiation	 factor	15;	also	known	as	macrophage	 inhibitory	 cytokine-1	 (MIC-1),	46	
NAG1,	PLAB	and	PDF)	is	a	stress-induced	cytokine	and	an	atypical	member	of	the	transforming	growth	47	
factor	beta	superfamily	(Tsai	et	al.,	2016).	Bootcov	et	al	originally	characterised	it	as	a	dimeric	protein	48	
secreted	 by	 activated	macrophages	 (Bootcov	 et	 al.,	 1997).	 In	 healthy	 animals,	 it	 is	 predominantly	49	























GFRAL	 expression	 appears	 to	 be	 strictly	 confined	 to	 the	 AP	 and	NTS.	 In	 addition	 to	 reporting	 the	73	
structure	 of	 GFRAL,	 these	 papers	 also	 showed	 that	 GFRAL	 KO	mice	 are	 resistant	 to	 the	 anorectic	74	
effects	of	exogenous	injected	GDF15	and	to	endogenously	secreted	GDF15	levels	induced	by	cisplatin	75	













that	 are	 involved	 in	 the	 regulation	 of	 GDF15	 expression	 and	 demonstrate	 activation	 of	 the	 ISR	 in	88	




























caloric	 restriction	 of	 varying	 intensity	 and	 duration.	 In	 Human	 Study	 2,	 GDF15	 concentrations	117	
increased	from	319.4	±	21.27	pg/ml	to	406.8	±	31.24	pg/ml	in	lean	healthy	volunteers	calorie	restricted	118	
for	2	days	(10	%	of	estimated	daily	energy	requirements)	(Figure	S1E).	119	
In	Human	 Study	 3,	 a	 cohort	 of	 obese	 participants	 consumed	 a	 low	 calorie	meal	 replacement	 diet	120	
(~1000	kcal/day)	for	28	days.	This	resulted	in	a	significant	reduction	in	body	weight	(-5.55	±	2.05	kg	121	






the	 fast	 (Figure	 1L).	 Meanwhile,	 circulating	 GDF15	 levels	 increased,	 peaking	 at	 48	 h	 of	 caloric	127	
restriction	(from	371.4	±	94.2	pg/ml	at	baseline	to	670.2	±	349.2	pg/ml	p=0.003).	Interestingly,	despite	128	
continuation	 of	 the	 calorie	 deprivation,	 GDF15	 levels	 gradually	 returned	 towards	 baseline	 levels	129	
although	remained	higher	than	starting	values	(441.2	±	151.3	pg/ml)	(Figure	1M).		130	


























As	 GDF15	 is	 a	 stress-responsive	 hormone,	 we	 wondered	 if	 more	 prolonged	 or	 severe	 nutritional	157	
stressors	 might	 be	 needed	 to	 induce	 its	 expression	 and	 secretion.	 To	 test	 this	 hypothesis,	 we	158	
undertook	a	prospective	longitudinal	study	in	mice	fed	either	a	chow	(CD)	or	high-fat	diet	(HFD)	from	159	
9	weeks	of	age	(Mouse	Study	3).	This	resulted	in	progressive	weight	gain	and	fat	mass	in	association	160	
with	 rising	 insulin	 and	 leptin	 levels	 (Figures	 2A-D).	 Glucose	 levels	were	 initially	 similar	 in	 the	 two	161	










work	 had	 suggested	 that	 ATF4	 and	 CHOP,	 key	 transcriptional	 regulators	 of	 the	 integrated	 stress	171	
response	 (ISR)	might	 be	 involved	 (Suzuki	 et	 al.,	 2017).	 The	 ISR	 is	 a	 cell	 autonomous	 integrator	 of	172	
diverse	cellular	stresses,	so	we	began	by	documenting		changes	in	GDF15	mRNA		in	mouse	embryonic	173	
















expression	 of	 both	 the	 downstream	 targets,	 ATF4	 and	 CHOP,	was	 increased,	 albeit	 to	 a	 different	190	
extent,	with	tunicamycin	and	thapsigargin	being	the	most	potent	inducers.		191	
Next,	we	used	a	combination	of	inhibitors	and	knockout-	or	knockdown	MEF	lines	to	test	the	roles	of	192	
various	 elements	 of	 the	 ISR	 pathway	 in	 the	 regulation	 of	GDF15.	 Firstly,	 using	 the	 PERK	 inhibitor,	193	
GSK2606414	(abbreviated	as	GSK	in	Figure	1),	or	the	EIF2a inhibitor,	ISRIB	(abbreviated	as	ISR	in	Figure	194	




EIF2a	 (Ser51-Ala)	 required	 for	 ISR	 activation	 (Figure	 3E).	 Similarly,	 moving	 downstream	 in	 the	199	
pathway,	 tunicamycin-induced	GDF15	expression	was	abolished	 in	ATF4	knockout	MEFs	 (Figure	3F	200	
and	Figure	S3E).		Furthermore,	siRNA-mediated	knockdown	of	CHOP	significantly	reduced	both	basal	201	
and	tunicamycin-induced	GDF15	expression	(Figure	3G	and	Figure	S3F).	Coupled	with	the	knowledge	202	
that	 circulating	 GDF15	 acts	 via	 GFRAL	 in	 the	 hindbrain,	 establish	 GDF15	 as	 a	 bona	 fide	 systemic	203	
endocrine	signal	of	the	ISR.	204	
In	order	to	establish	if	the	ISR	is	indeed	responsible	for	the	observed	induction	of	GDF15	in	long-term	205	
HF	 fed	mice,	we	next	evaluated	expression	of	ATF4	and	CHOP	mRNA	 in	 the	same	panel	of	 tissues	206	
assessed	for	GDF15	expression	(Mouse	Study	3).	These	data	confirmed	that	ATF4	and	CHOP	mRNA	207	








was	 being	 induced	 in	macrophages,	 or	 other	 stromovascular	 fraction	 (SVF)	 cells,	 or	 in	 adipocytes	215	
themselves.	The	data	suggest	that	GDF15	mRNA	is	induced	in	both	fractions	(Figure	S3J).	However,	216	
lipid	 laden	macrophages	may	 ‘contaminate’	 the	 adipocyte	 fraction	 as	 the	 separation	 is	 based	 on	217	
flotation	so	we	went	on	to	check	for	this	by	analysing	mRNA	expression	of	Plin1	(an	adipocyte	marker)	218	
and	F4/80	in	each	of	the	fractions.	These	data	suggest	that	macrophages	are	present	in	the	adipocyte	219	
fraction	 so	 it	 remains	 possible	 that	 the	 apparent	 increase	 in	GDF15	mRNA	 is	 largely	 coming	 from	220	
macrophages,	though	we	cannot	formally	exclude	a	contribution	from	adipocytes	themselves.		221	
From	 these	 data,	 it	 is	 clear	 that	 in	mice,	 GDF15	 expression	 is	 responsive	 to	 chronic	 conditions	 of	222	
overnutrition	that	manifest	with	changes	in	GDF15	within	adipose	tissue	(white	and	brown)	and	the	223	
liver.	These	findings	are	consistent	with	reported	increases	in	GDF15	levels	in	ob/ob	mice	and	in	obese	224	

















al.,	 2017).	 Activation	 of	 the	 GDF15	 receptor	 (GFRAL)	 has	 also	 been	 linked	 to	 subsequent	 cFos	242	
activation	in	the	parabrachial	nucleus	(PBN)	which	has	in	turn	been	linked	to	appetite	suppression	in	243	
response	to	meal-related	peptides,	as	well	as	ingestion	of	toxins,	mimicked	by	lithium	chloride	and	244	
lipopolysaccharide	 (Carter	 et	 al.,	 2013;	 Hsu	 et	 al.,	 2017).	 Thus	 we	 hypothesized	 that	 GDF15	245	
administration	 might	 result	 in	 conditioned	 taste	 aversion	 (CTA),	 which	 occurs	 when	 an	 animal	246	
associates	 the	 taste	 of	 a	 normally	 favoured	 food	 with	 symptoms	 caused	 by	 a	 concomitantly	247	
administered	toxic	or	aversive	substance.	248	
In	Mouse	Study	5,	 	we	 first	 assessed	 the	ability	of	GDF15	 to	 lower	 food	 intake	 in	 a	 concentration	249	
dependent	manner.	A	single	subcutaneous	injection	of	GDF15	in	mice	acutely	increased	plasma	GDF15	250	
concentration,	with	maximum	exposures	occurring	1	and	4	hours	post-treatment	(Figure	4E).	GDF15	251	
treatment	 resulted	 in	 a	 corresponding	 dose-dependent	 reduction	 of	 food	 intake	 which	 reached	252	












short	term	overfeeding	 induced	a	small	 increase	 in	FGF21	 levels	whereas	prolonged	HFD	exposure	264	
was	associated	with	a	robust	increase	in	FGF21	levels	(Figures	S4E,F).	Interestingly,	although	FGF21	265	
mRNA	increased	in	similar	tissues	as	GDF15,	within	WAT,	FGF21	seemed	to	originate	from	adipocytes	266	
themselves	 rather	 than	 macrophages	 (Figures	 5G,H).	 Lysine-deficient	 diet	 in	 mice	 also	 elicited	 a	267	
significant	increase	in	hepatic	FGF21	mRNA	(Figures	S4I).	In	cells,	FGF21	responses	to	activation	of	the	268	
ISR	 largely	 mirrored	 the	 GDF15	 responses	 with	 one	 notable	 exception;	 that	 being	 exaggerated	269	
induction	rather	than	amelioration	of	the	FGF21	response	to	TN	in	CHOP	knockdown	cells	(Figures	S4J-270	
N).	 These	 results	 suggest	 that	 whilst	 the	 ISR	 pathway	 regulates	 both	 hormones,	 the	 molecular	271	
mechanisms	 downstream	 of	 ATF4	 are	 distinct.	 These	 data	were	 corroborated	 by	 the	 finding	 that	272	
circulating	FGF21	and	hepatic	FGF21	mRNA	levels	were	significantly	increased	in	mice	following	a	24	273	
hour	fast,	despite	the	lack	of	a	significant	change	in	ATF4	or	CHOP	mRNA	expression	(Figures	S4O-R).	274	







involved	 in	 physiological	 settings	 of	 under-	 and	 over-nutrition.	 To	 this	 end	 we	 combined	 cellular	281	
studies	with	in	vivo	work	in	mice	and	humans	to	establish	that	GDF15	expression	is	highly	responsive	282	
to	activation	of	the	integrated	stress	response	in	a	range	of	cell	types	and	that	 its	 induction	in	this	283	
setting	 is	dependent	upon	ATF4	and	CHOP.	The	 idea	that	cellular	stress	might	be	translated	 into	a	284	
systemic	response	initially	emerged	from	work	in	C.elegans	where	an	induction	of	the	mitochondrial	285	
unfolded	 protein	 response	 (UPRmt)	 in	 neurons	 led	 to	 changes	 in	 mitochondria	 within	 physically	286	







regulators	 of	 post-prandial	 satiety	 (e.g	 enteroendocrine	 hormones	 such	 as	 GLP-1)	 or	 longer	 term	294	
hormonal	regulators	of	nutrient	stores	(e.g	leptin).	In	contrast	to	GLP-1,	and	consistent	with	previous	295	
reports,	(Schernthaner-Reiter	et	al.,	2016;	Tsai	et	al.,	2015)	GDF15	did	not	respond	acutely	to	a	meal	296	
or	 a	 glucose	 load	 in	 humans.	 In	mice	 fasted	 for	 24	 h,	 there	was	 no	 change	 in	 circulating	 GDF15,	297	
whereas	the	predicted	fall	in	leptin	levels	and	rise	in	FGF21	levels	was	seen.	In	humans,	48	h	of	severe	298	
caloric	 restriction	 in	 lean	 healthy	 volunteers	 resulted	 in	 a	 significant	 but	 small	 increase	 in	 GDF15	299	














As	 recently	 summarised	 by	 Tsai	 et	 al,	 the	 relationship	 between	 circulating	 GDF15	 and	 obesity	 in	314	









































but	 does	 not	 produce	 CTA	 (Thiele	 et	 al.,	 1997).	 The	 lateral	 parabrachial	 nucleus	 (PBN),	 medial	355	
thalamus,	and	basolateral	nucleus	of	the	amygdala	are	essential	for	both	acquisition	and	retention	of	356	















produce	a	CTA	 response	 in	 rodents	and	activate	 the	 lateral	PBN	 (Thiele	et	al.,	 1997).	With	 careful	371	
titration,	most	humans	can	tolerate	therapeutic	doses	of	GLP-1	receptor	agonists,	though	nausea	and	372	
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(G)	GDF15	mRNA	expression	 in	subcutaneous	 -	 (SAT),	epididymal	 -	 (EAT)	and	brown	(BAT)	adipose	674	
tissue,	liver,	soleus	muscle	and	kidney	isolated	from	C57Bl/6J	male	mice	fed	a	CD	or	HFD	for	18	weeks	675	














treated	 with	 Tn	 (5	 µg/ml)	 for	 6	 h.	 (H)	 Diagram	 outlining	 pathway	 by	 which	 GDF15	 and	 FGF21	689	
expression	 is	 regulated	 by	 TN.	 mRNA	 expression	 is	 presented	 as	 fold-expression	 relative	 to	 its	690	
respective	 control	 treatment	 for	 each	 cell	 type	 (set	 at	 1)	 or	 TN	 treated	 samples	 (set	 as	 100)	with	691	
normalisation	to	HPRT	gene	expression	in	MEFs	and	GAPDH	in	human	cells.	Data	is	expressed	as	mean	692	
±	SD	from	at	least	three	independent	experiments.	***p	<	0.001	vs	control	(con)	for	A	and	B,	and	vs	693	



































years	and	BMI	of	25.05	 	±	 	3.73	kg/m2.	Both	studies	were	completed	at	 the	NIHR	Wellcome	Trust	727	
Clinical	 Research	 Facility	 and	 the	 Wellcome-MRC	 Translational	 Research	 Facility,	 Cambridge	728	
Biomedical	Campus,	UK.	Ethical	approval	was	obtained	 from	the	East	of	England	Cambridge	South	729	
research	ethics	committee	Ref:	16/EE/0338	and	the	East	of	England	Cambridgeshire	and	Hertfordshire	730	























































with	 group	 housing	 (2	 or	 3	 per	 cage)	 in	 a	 12	 h	 light/12	 h	 dark	 cycle	 (lights	 on	 06:00–18:00),	784	
temperature-controlled	(20-24	°C)	facility,	with	ad	libitum	access	to	food	and	water.	All	mice	were	fed	785	
either	ad	libitum	or	as	stated	otherwise	prior	to	harvesting	tissue	and	serum	analysis.	This	research	786	
was	 regulated	 under	 the	 Animals	 (Scientific	 Procedures)	 Act	 1986	 Amendment	 Regulations	 2012	787	





dark	 cycle	 (lights	 on	 08:00-20:00).	 Animal	 experiments	were	 carried	 out	 in	 accordance	with	 INRA	793	
guidelines	 in	 compliance	 with	 European	 animal	 welfare	 regulation.	 Mouse	 maintenance	 and	 all	794	
experiments	have	been	approved	by	the	institutional	animal	care	and	use	committee,	in	conformance	795	
with	 French	 and	European	Union	 laws	 (permission	 to	 experiment	on	mice	 #5558,	 animal	 facilities	796	
agreement	D6334515,	GMO	agreement	#4713).	797	
For	the	lysine	nutritional	deficiency	experiment,		an	experimental	diet	was	manufactured	in	the	INRA	798	



















carcinoma	 obtained	 from	 ATCC)	 were	 cultured	 in	 the	 same	 media	 as	 MEFs	 but	 without	 2-817	









On	 the	day	before	 the	assessment	all	 participants	 received	a	 standardised	evening	meal	 at	18:00,	827	
before	commencing	an	overnight	fast.	The	energy	content	of	the	meal	was	one	third	of	a	participant’s	828	
daily	 requirements	 estimated	 from	 predicted	 resting	metabolic	 rate	 and	multiplied	 by	 an	 activity	829	
factor	of	1.35	(Schofield,	1985;	Westerterp,	1999).	Meal	composition	consisted	of	30–35	%	fat,	12–15	830	
%	protein	and	50–55	%	carbohydrate	by	energy.	Anthropometric	measurements	were	acquired	for	all	831	
participants	 on	 arrival	 to	 the	 clinical	 research	 facility.	 Participants	 were	 cannulated	 prior	 to	832	
administration	 of	 an	 oral	 liquid	meal	 consisting	 of	 a	 200	ml	 EnsureÒ	 Plus	 (Total	 energy	 330	 kcal;	833	
Protein	16.7	%,	Carbohydrate	53.8	%,	Fat	29.5	%)	or	a	glucose	drink	(50	g	anhydrous	glucose	in	200	ml	834	




stored	 at	 -70	 °C	 until	 the	 time	 of	 biochemical	 analysis.	 Assays	were	 completed	 by	 the	 Cambridge	839	
Biochemical	 Assay	 Laboratory,	 University	 of	 Cambridge.	 Serum	 GDF15	 measurements	 were	840	
undertaken	with	antibodies	&	standards	from	R&D	Systems	(R&D	Systems	Europe,	Abingdon	UK)	using	841	
a	 microtitre	 plate-based	 two-site	 electrochemiluminescence	 immunoassay	 using	 the	 MesoScale	842	
Discovery	assay	platform	(MSD,	Rockville,	Maryland,	USA).	Plasma	glucose	was	determined	using	a	843	
hexokinase	 assay	 on	 a	 Siemens	 Dimension	 ExL	 Analyser.	 Plasma	 insulin	 measurements	 using	 the	844	
Diasorin	 Liaisonâ	 XL	 automated	 	 onestep	 chemiluminesence	 immunoassay	 (Diasorin	 S.p.A,	 13040	845	


















site	electrochemiluminescence	 immunoassay	using	 the	MesoScale	Discovery	assay	platform	 (MSD,	863	
Rockville,	Maryland,	USA).	864	
Human	study	3:	Low	calorie	diet	intervention	865	
At	 day	 0,	 prior	 to	 initiation	 of	 the	 low-calorie	 dietary	 (LCD)	 intervention,	 baseline	 fasting	 blood	866	
sampling	and	anthropometry	were	measured.	Participants	were	provided	with	dietary	counselling	and	867	
meal-replacement	 shakes	 at	 this	 and	 subsequent	 visits,	 and	 the	 LCD	 was	 initiated.	 Participants	868	
received	a	 low-calorie	diet	for	8	weeks	at	approximately	1000	kcal	per	day,	replacing	2	meals	with	869	
approximately	600	kcal	of	meal	replacement	shakes	followed	by	a	dinner	of	approximately	400	kcal.		870	
Dinners	 were	 chosen	 from	 an	 approved	 list	 of	 Lean	 Cuisine	 and	 Healthy	 Choice	 brand	 meals.	871	





Systems	 (R&D	 Systems	 Europe,	 Abingdon	 UK)	 using	 a	 microtitre	 plate-based	 two-site	877	
electrochemiluminescence	 immunoassay	 using	 the	 MesoScale	 Discovery	 assay	 platform	 (MSD,	878	







permitted	 throughout	 the	 study.	During	 the	 study,	weight	 	 (mean	±	 SD)	 fell	 from	79.6	±	5.0	 kg	at	885	
baseline	 to	73.8	±	4.8	kg	after	1	week	of	 fasting.	The	measurements	of	mean	±	SD	body	 fat	were	886	








&	standards	 from	R&D	Systems	 (R&D	Systems	Europe,	Abingdon	UK).	 	A	 two-site	microtitre	plate-895	
based	Delfia	assay	measured	Leptin.	GDF15	was	measured	using	a	microtitre	plate-based	 two-site	896	
electrochemiluminescence	 immunoassay	 using	 the	 MesoScale	 Discovery	 assay	 platform	 (MSD,	897	
Rockville,	Maryland,	USA).	The	analytic	processes	of	b-Hydroxybutyrate	were	conducted	according	to	898	
the	 manufacturer’s	 instructions.	 Plasma	 concentration	 of	 b-Hydroxybutyrate	 (mmol/l)	 were	899	


























GmBH,	 Marburg,	 Germany).	 Serum	 Leptin	 and	 GDF15	 measurements	 were	 undertaken	 at	 the	925	
Cambridge	Biochemical	Assay	Laboratory,	University	of	Cambridge	using	antibodies	&	standards	from	926	
R&D	Systems	(R&D	Systems	Europe,	Abingdon	UK).		A	two-site	microtitre	plate-based	Delfia	assay	was	927	
used	 to	 measure	 Leptin.	 GDF15	 was	 measured	 using	 a	 microtitre	 plate-based	 two-site	928	
electrochemiluminescence	 immunoassay	 using	 the	 MesoScale	 Discovery	 assay	 platform	 (MSD,	929	











final	 24	 h	 period,	 the	 diet	 was	 returned	 to	 the	 baseline	 components	 and	 the	 same	 baseline	941	
assessments	were	performed	at	the	end	of	the	8	week	overfeeding.	Participants	ate	all	food	provided	942	
during	the	study	period.	Plasma	glucose	was	measured	using	a	glucose	oxidase	electrode	(DXC	600	943	
Pro;	 Beckman	 Coulter),	 and	 insulin	was	measured	 by	 an	 immunoassay	 (Immulite	 2000;	 Siemens).	944	
Plasma	 free	 fatty	 acids	 (FFAs)	 were	 measured	 with	 a	 high-sensitivity	 Wako	 kit.	 Plasma	 GDF15	945	
measurements	 were	 undertaken	 with	 antibodies	 &	 standards	 from	 R&D	 Systems	 (R&D	 Systems	946	









same	 grouped	 arrangement	 as	 during	 the	 maintenance	 period.	 Home	 cage	 bedding	 was	 also	955	
















using	 a	 glucometer	 (AlphaTrak2;	 Abbot	 Laboratories)	 and	 glucose	 strips	 (AlphaTrak2	 test	 2	 strips,	972	
Abbot	Laboratories,	Zoetis).	Tissues	were	harvested	and	weighed.		973	
For	the	long-term	chronic	high	fat	diet	study	(Mouse	Study	3),	9	week-old	male	mice	were	subjected	974	
to	either	a	 chow	or	high	 fat	diet	 (as	 in	 short-term	HFD)	over	a	period	of	18	weeks.	All	mice	were	975	


























GDF15	was	administered	via	subcutaneous	 (SC)	 injection	as	a	single	dose	 in	all	mouse	studies.	LiCl	1001	
(Sigma)	was	also	prepared	 in	saline	and	administered	via	SC	 injection	as	a	single	dose	 in	all	mouse	1002	
studies.	Mice	were	acclimated	(up	to	3	days)	to	drinking	from	two	water	bottles	to	confirm	lack	of	side	1003	
preference	prior	to	habituation.	Mice	were	then	habituated	to	overnight	water	restriction	(days	1-3)	1004	
followed	by	1	h	water	bottle	presentation	 (two	bottles)	and	saline	SC	 injection.	On	day	4	 to	begin	1005	
































and	 processed	 through	 a	 Qiashredder	 with	 total	 RNA	 extracted	 using	 the	 RNeasy	 isolation	 kit	1037	
according	to	manufacturer’s	instructions	(Qiagen).		Meanwhile	for	mice,	tissues	were	harvested	and	1038	
immediately	snap	frozen	in	liquid	nitrogen	and	stored	at	-80	°C	until	further	analysis.	For	RNA	isolation,	1039	






some	 instances	 treated	 with	 DNAse1	 on-column)	 using	 the	 RNeasy	 isolation	 kit	 following	 the	1046	
manufacturer´s	instructions.		1047	
RNA	concentration	and	quality	was	determined	by	Nanodrop.	400	ng	-	500	ng	of	total	RNA	was	treated	1048	
with	 DNAase1	 (Thermofisher	 Scientific)	 and	 then	 converted	 to	 cDNA	 using	 MMLV	 Reverse	1049	
Transcriptase	 with	 random	 primers	 (Promega).	 Quantitative	 RT-PCR	 was	 carried	 out	 with	 either	1050	
TaqMan™	Universal	PCR	Master	Mix	or	SYBR	Green	PCR	master	mix	on	the	QuantStudio	7	Flex	Real	1051	
time	PCR	system	(Applied	Biosystems).	All	reactions	were	carried	out	in	either	duplicate	or	triplicate	1052	
and	 Ct	 values	 were	 obtained.	 Relative	 differences	 in	 the	 gene	 expression	 were	 normalized	 to	1053	
	 30	






for	 serum	analysis.	Mouse	 leptin	and	 insulin	were	measured	 simultaneously	using	a	2-plex	Mouse	1060	
Metabolic	 immunoassay	 kit	 from	 Meso	 Scale	 Discovery	 Kit	 (Rockville,	 MD,	 USA).	 The	 assay	 was	1061	
performed	 according	 to	 the	 manufacturer’s	 instructions	 and	 using	 calibrators	 provided	 by	 MSD.	1062	


























in	 the	 figure	 legends,	differences	between	means	were	assessed	by	 two-tailed	Student's	 t	 tests	or	1088	
One-way	 ANOVA	 or	 Two-way	 ANOVA	 with	 Bonferroni	 multiple	 comparisons	 test	 using	 either	1089	
GraphPad	Prism	software	(GraphPad,	San	Diego)	or	with	SAS	version	9.4,	Cary,	N.	Carolina.	Statistical	1090	
significance	was	defined	as	p	<	0.05.			1091	
Data	 from	 human	 studies	 was	 analysed	 using	 GraphPad	 Prism	 software	 (GraphPad,	 San	 Diego).	1092	
Parametric	quantitative	data	is	expressed	as	mean	±	SEM	and	the	difference	in	the	mean	was	assessed	1093	
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HS6-Human	study	6	 (K-M):	 (K)	Body	weight	 (L)	 leptin	and	 (M)	GDF15	 following	 four	or	eight	weeks	of	
overfeeding	 (additional	 40	 %	 weight	 maintenance	 energy	 requirements)	 in	 20	 volunteers.	 Data	 is	
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Figure	 S3	 (related	 to	 Figure	 3).	 GDF15	 is	 regulated	 by	 the	 cellular	 integrated	 stress	 (ISR)	 response	
pathway.	(A)	GDF15	mRNA	expression	and	(B)	immunoblot	analysis	from	cell	lysates	for	ISR	components	
in	 Hela,	 HuH7	 and	 A549	 cells	 treated	with	 cobalt	 chloride	 (CoCl2,	 625	 uM),	 thapsigargin	 (Tg,	 1	µM),	
tunicamycin	(Tn	5	µg/ml)	or	L-Histidinol	(His,	1	mM)	for	6	h.		Note	for	(B),	the	arrows	denote	GDF15	protein	
and	 that	Tn	 treatment	 causes	a	mobility	 shift	 that	we	hypothesize	 is	due	 to	an	 impairment	of	GDF15	
glycosylation.	Red	asterisks	indicates	a	non-specific	band.	Whilst	GDF15	mRNA	was	induced	in	(A),	there	
was	 no	 detectable	GDF15	 protein	 in	 A549	 cells	 in	 cell	 lysates.	 (C)	 GDF15	mRNA	 expression	 in	 3T3-L1	
preadipocytes	 treated	 with	 Tn	 (5	 µg/ml)	 for	 6	 h.	 (D)	 Immunoblot	 analysis	 from	 cell	 lysates	 for	 ISR	
components	in	WT	MEFs	treated	with	TN	in	the	presence	or	absence	of	the	PERK	inhibitor	GSK2606414	
(GSK,	200	nM)	or	eIF2a	 inhibitor	 ISRIB	(ISR,	100	nM)	or	(E)	 in	Tn-treated	WT	or	ATF4	KO	MEFs.	GDF15	
mRNA	is	presented	as	fold	expression	relative	to	its	respective	control	treatment	for	each	cell	type	(set	at	
1),	normalised	to	HPRT	gene	expression	in	MEFs	and	3T3-L1	and	GAPDH	in	human	cells.	Data	is	expressed	
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	KEY RESOURCES TABLE 
The table highlights the genetically modified organisms and strains, cell lines, reagents, software, and 
source data essential to reproduce results presented in the manuscript. Depending on the nature of the 
study, this may include standard laboratory materials (i.e., food chow for metabolism studies), but the 
Table is not meant to be comprehensive list of all materials and resources used (e.g., essential chemicals 
such as SDS, sucrose, or standard culture media don’t need to be listed in the Table). Items in the Table 
must also be reported in the Method Details section within the context of their use. The number of 
primers and RNA sequences that may be listed in the Table is restricted to no more than ten each. If 
there are more than ten primers or RNA sequences to report, please provide this information as a 
supplementary document and reference this file (e.g., See Table S1 for XX) in the Key Resources Table. 
Please note that ALL references cited in the Key Resources Table must be included in the 
References list. Please report the information as follows: 
• REAGENT or RESOURCE: Provide full descriptive name of the item so that it can be identified and 
linked with its description in the manuscript (e.g., provide version number for software, host source 
for antibody, strain name). In the Experimental Models section, please include all models used in the 
paper and describe each line/strain as: model organism: name used for strain/line in paper: 
genotype. (i.e., Mouse: OXTRfl/fl: B6.129(SJL)-Oxtrtm1.1Wsy/J). In the Biological Samples section, 
please list all samples obtained from commercial sources or biological repositories. Please note that 
software mentioned in the Methods Details or Data and Software Availability section needs to be 
also included in the table. See the sample Table at the end of this document for examples of how to 
report reagents. 
 
• SOURCE: Report the company, manufacturer, or individual that provided the item or where the item 
can obtained (e.g., stock center or repository). For materials distributed by Addgene, please cite the  
article describing the plasmid and include “Addgene” as part of the identifier. If an item is from 
another lab, please include the name of the principal investigator and a citation if it has been 
previously published. If the material is being reported for the first time in the current paper, please 
indicate as “this paper.” For software, please provide the company name if it is commercially 
available or cite the paper in which it has been initially described. 
 
• IDENTIFIER: Include catalog numbers (entered in the column as “Cat#” followed by the number, 
e.g., Cat#3879S). Where available, please include unique entities such as RRIDs, Model Organism 
Database numbers, accession numbers, and PDB or CAS IDs. For antibodies, if applicable and 
available, please also include the lot number or clone identity. For software or data resources, 
please include the URL where the resource can be downloaded. Please ensure accuracy of the 
identifiers, as they are essential for generation of hyperlinks to external sources when available. 
Please see the Elsevier list of Data Repositories with automated bidirectional linking for details. 
When listing more than one identifier for the same item, use semicolons to separate them (e.g. 
Cat#3879S; RRID: AB_2255011). If an identifier is not available, please enter “N/A” in the column.   
o A NOTE ABOUT RRIDs: We highly recommend using RRIDs as the identifier (in particular for 
antibodies and organisms, but also for software tools and databases). For more details on how 
to obtain or generate an RRID for existing or newly generated resources, please visit the RII or 
search for RRIDs. 
 
Please use the empty table that follows to organize the information in the sections defined by the 
subheading, skipping sections not relevant to your study. Please do not add subheadings. To add a row, 
place the cursor at the end of the row above where you would like to add the row, just outside the right 
border of the table. Then press the ENTER key to add the row. Please delete empty rows. Each entry 
must be on a separate row; do not list multiple items in a single table cell. Please see the sample table at 
the end of this document for examples of how reagents should be cited. 
  
	TABLE FOR AUTHOR TO COMPLETE 
Please upload the completed table as a separate document. Please do not add subheadings to the Key 
Resources Table. If you wish to make an entry that does not fall into one of the subheadings below, please contact 
your handling editor. (NOTE: For authors publishing in Current Biology, please note that references within the KRT 
should be in numbered style, rather than Harvard.) 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
GDF15 (G-5) Santa Cruz Cat# sc-377195 
GADD 153 (B-3) Santa Cruz Cat# sc-7351 
RRID:AB_627411 
Phospho S51 EIF2a Epitomics/Abcam Cat# ab32157 
RRID:AB_732117 
 
ATF4 Dr David Ron (CIMR) (Harding et al., 2000) 
Calnexin Abcam Cat# ab75801 
RRID:AB_1310022 
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling Technologies Cat# 7074 
RRID:AB_2099233 
Anti-mouse IgG, HRP-linked Antibody Cell Signaling Technologies Cat# 7076 
RRID:AB_330924 
Biological Samples   
C57Bl/6J mice tissues Charles River JAX™ C57BL/6J 
RRID:IMSR_JAX:000664 




Human samples (Blood) Various See Methods for details 
   
   
Chemicals, Peptides, and 
Recombinant Proteins 
  
Recombinant Human GDF15 Peprotech Cat# 120-28 
Lithium Chloride Sigma Cat# LX0331 
Tunicamycin Sigma Cat# T7765 
Thapsigargin Sigma Cat# T9033 
Cobalt(II) chloride hexahydrate Sigma Cat# C8661 
L-Histidinol dihydrochloride Sigma Cat# H6647 
ISRIB Sigma Cat# SML0843 
PERKi - GSK2606414 Calbiochem Cat# 516535 
TRI Reagent (Triazol) Sigma Cat# T9424 
Chloroform Honeywell Cat# C2432 
Ethanol, puriss. p.a., absolute, ≥99.8% (GC) Sigma Cat# 32221-M 
DMEM Sigma Cat# D6546 
D-PBS Sigma Cat# D8537 
Hanks' Balanced Salt Solution Sigma Cat# H9269 
L-Glutamine Sigma Cat# G7513 
Penicillin-Streptomycin Sigma Cat# P0781 
MEM Non-essential Amino Acid Sigma Cat# M7145 
	Sodium pyruvate Sigma Cat# S8636 
2-Mercaptoethanol Gibco Cat# 31350-010 
FBS Gibco Cat# 10270-106 
FetalClone™ II Serum Hyclone Cat# SH30066.03 
Sybr Green MasterMix Applied Biosystems Cat# 4309155 
Taqman MasterMix Applied Biosystems Cat# 4304437 
cOmplete™, Mini Protease Inhibitor Cocktail Sigma Cat# 11836153001 
PhosSTOP™ Sigma Cat# 4906845001 
Random primers Promega Cat# C1181 
RNasin Plus Ribonuclease inhibitor Promega Cat# N2611 
MMLV Reverse Transcriptase Promega Cat# M1701 
DNase1 Qiagen Cat# 79254 
DNase1 Thermofisher Scientific Cat# 18068015 
Lipofectamine™ RNAiMAX Invitrogen Cat# 13778-150 
Collagenase Type II from Clostridium 
histolyticum 
Sigma Cat# C6885 
NuPAGE™ 4-12% Bis-Tris Protein Gels, 1.5 
mm, 10-well 
Novex Cat# NP0335BOX 
NuPAGE™ MOPS SDS Running Buffer (20X) Novex Cat# NP0001 
NuPAGE™ LDS Sample Buffer (4X) Novex Cat# NP0007 
iBlot™ Transfer Stack, nitrocellulose, regular 
size 
Invitrogen Cat# IB301001 
Dual Color Standards BIO-RAD Cat# 1610374 
Bovine Serum Albumin Sigma Cat# A7906 
Immobilon Western (Chemiluminescent HRP 
Substrate) 
Millipore Cat# WBKLS0500 
ECL Western Blotting Detection Reagents GE Healthcare Cat# RPN2106 
Dolethal 200mg/ml Solution for injection Vetoquinol UK Ltd NA 
Biological kits   
RNAeasy Mini  Kit Qiagen Cat# 74106 
Qiashredder Qiagen Cat# 79656 
Human total GLP-1 Meso Scale Discovery Cat# K150JVC-1 
Human Active GLP-1 R&D Systems Cat#  DY957 
Human Insulin Diasorin Cat# 310360 
Human GDF15 Elisa R&D Systems Cat# DY957 
Human FGF21 Elisa R&D Systems Cat# DF2100 
Human Leptin Elisa In-house platform system 
using R&D Leptin: Cat # 





Mouse GDF15 Elisa R&D Systems Cat# DY6385 
Mouse FGF21 Elisa R&D Systems Cat# MF2100 
Mouse Leptin/insulin 2-Plex Meso Scale Discovery Cat# K15124C 
Experimental Models: Cell Lines   
Mouse Embryonic Fibroblasts (MEFs) Dr David Ron (CIMR) (Scheuner et al., 2001; 
Harding et al., 2003) 
HeLa ATCC Cat# CCL-2 
RRID:CVCL_0030 




A549 ATCC Cat# CCL-185	
RRID:CVCL_0023 




M. musculus: C57Bl/6J mice strain Charles River  JAX™ C57BL/6J 
RRID:IMSR_JAX:000664 










Oligonucleotides   
Control siRNA Dharmacon Cat# D-001810-10-20 
DDIT3 siRNA smartpool On-target Plus Dharmacon Cat# L-062068-00-0005 
Human GDF15 Taqman assay Thermo Fisher Scientific Cat# Hs00171132_m1   
Human FGF21 Taqman assay Thermo Fisher Scientific Cat# Hs00173927_m1 
Mouse GDF15 Taqman assay Thermo Fisher Scientific Cat# Mm00442228_m1 
Mouse FGF21 Taqman assay Thermo Fisher Scientific Cat# Mm00840165_g1 
Human GAPDH Taqman assay Thermo Fisher Scientific Cat# Hs02758991_g1 
Human HPRT Taqman assay Thermo Fisher Scientific Cat# Hs02800695_m1 
Mouse HPRT Forward 
(AGCCTAAGATGAGCGCAAGT) 
Mouse HPRT Reverse 
(GGCCACAGGACTAGAACACC) 
This paper NA 
 
 
Mouse B2M Forward 
(ACTGATACATACGCCTGCAGAGTT)	
Mouse B2M Reverse 
(TCACATGTCTCGATCCCAGTAGA) 
This paper NA 
 
 
Mouse 36b4 Forward 
(AGATGCAGCAGATCCGCAT)	
Mouse 36b4 Reverse 
(GTTCTTGCCCATCAGCACC) 
This paper NA 
 
 
Mouse F4/80 Forward 
CAGATACAGCAATGCCAAGCA 
Mouse F4/80 Reverse 
GATTGTGAAGGTAGCATTCACAAGTG 
Mouse F4/80 Probe 
FAM-	GCAGGGCAGGGATCTTGGTTATGC-
TAMRA 
This paper NA 
Mouse CHOP Forward 
(CCACCACACCTGAAAGCAGAA)	
Mouse CHOP Reverse 
(AGGTGAAAGGCAGGGACTCA) 
This paper (Oslowski and Urano, 
2013) 
Mouse ATF4 Forward 
(GGGTTCTGTCTTCCACTCCA)	
Mouse ATF4 Reverse 
(AAGCAGCAGAGTCAGGCTTTC) 
This paper Oslowski and Urano, 2013) 
 
Software and Algorithms   
GraphPad PRISM 7 1992-2017 GraphPad 
Software, INC 
RRID:SCR_000306 
Illustrator (CS6) Adobe RRID:SCR_010279 
Photoshop (CS6) Adobe RRID:SCR_014199 
Other   
	Chow diet (mouse studies) Safe Diets Cat# R105-25 
Chow diet (mouse studies) Purina (Lab Diet) Cat# 5053 
45% High Fat Diet (mouse studies) Research Diets Cat# D12451i 
E EnsureÒ Plus  Abbot Laboratories NA 
Equipment   
ImageQuant LAS 4000 GE Healthcare Cat# 28955810 
Nanodrop 2000 Thermofisher Scientific NA 
FastPrep-24 MP Biomedical Cat# 116004500 
AlphaTrack2 Glucometer Abbot Laboratories Cat# CFMU305-H0201 
AlphaTrack2 strips Zoetis Cat# 71681-01 
Hematocrit tubes Na-Heparinized Hawksley Cat# 01605-00 
Microtube 1.1 ml Z Gel Sarstedt AG & Co Cat#  41.1378.005 
Microtube 1.1 ml Z Gel Sarstedt AG & Co Cat#  41.1500.005 
Lysing Matrix D, 2 mL Tube MP Biomedical Cat# 116913100 
Sterile Cell strainer (100 µm nylon mesh) Fisherbrand 22363549 
Minispec LF series (TD-NMR) Bruker Cat# LF50 
Lunar PIXImus Mouse Densitometer GE Healthcare Systems NA 
iBlot® Dry Blotting System Invitrogen NA 
PowerPac™ Universal Power Supply BIO-RAD Cat# 1645070 
XCell SureLock™ Mini-Cell Electrophoresis 
System 
Invitrogen Cat# EI0001 
QuantStudio 7 Flex Real-Time PCR System 
 
ThermoFisher Scientific Cat# 4485701	
 
	
 
 
 
 
 
 
 
 
 
 
